<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7803146</journal-id>
<journal-id journal-id-type="pubmed-jr-id">5975</journal-id>
<journal-id journal-id-type="nlm-ta">Muscle Nerve</journal-id>
<journal-id journal-id-type="iso-abbrev">Muscle Nerve</journal-id>
<journal-title-group>
<journal-title>Muscle &amp; nerve</journal-title>
</journal-title-group>
<issn pub-type="ppub">0148-639X</issn>
<issn pub-type="epub">1097-4598</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28877560</article-id>
<article-id pub-id-type="pmc">5759757</article-id>
<article-id pub-id-type="doi">10.1002/mus.25953</article-id>
<article-id pub-id-type="manuscript">NIHMS929102</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Genetic Modifiers of Duchenne and Facioscapulohumeral Muscular Dystrophies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hightower</surname>
<given-names>Rylie M.</given-names>
</name>
<degrees>BSN</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<!--<email>rylieh@uab.edu</email>-->
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alexander</surname>
<given-names>Matthew S.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">4</xref>
<!--<email>malexander@peds.uab.edu</email>-->
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>University of Alabama at Birmingham Graduate School of Biomedical Sciences, Birmingham, AL 35294</aff>
<aff id="A2">
<label>2</label>Department of Pediatrics, Division of Neurology at Children’s of Alabama and the University of Alabama at Birmingham, Birmingham, AL, 35294</aff>
<aff id="A3">
<label>3</label>Department of Genetics, the University of Alabama at Birmingham, Birmingham, AL, 35294</aff>
<author-notes>
<corresp id="FN1"><label>4</label>Corresponding author: Correspondence should be directed to: Matthew S. Alexander, PhD, University of Alabama at Birmingham, Children’s of Alabama, 1918 University Blvd. MCLM 464 Box 96, Birmingham, AL 35294, <email>malexander@peds.uab.edu</email>, Office Phone: 1(205)-934-7790, Office Fax: 1(205)-996-0965</corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Statement of Financial Disclosures and Conflicts of Interest</bold>
</p>
<p>The authors (R.M.H. and M.S.A.) declare no financial holdings or conflicts of interest for all work presented in this manuscript.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>20</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>09</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>57</volume>
<issue>1</issue>
<fpage>6</fpage>
<lpage>15</lpage>
<!--elocation-id from pubmed: 10.1002/mus.25953-->
<abstract>
<p id="P1">Muscular dystrophy is defined as the progressive wasting of skeletal muscles that is caused by inherited or spontaneous genetic mutations. Next-generation sequencing (NGS) has greatly improved the accuracy and speed of diagnosis for different types of muscular dystrophy. Advancements in depth of coverage, convenience, and overall reduced cost, have led to the identification of genetic modifiers that are responsible for phenotypic variability in affected patients. These genetic modifiers have been postulated to explain key differences in disease phenotypes including age of loss of ambulation, steroid-responsiveness, and the presence or absence of cardiac defects in patients with the same form of muscular dystrophy. Here we review and highlight recent findings on genetic modifiers of Duchenne and Facioscapulohumeral muscular dystrophies based on animal and clinical studies. These genetic modifiers hold great promise to be developed into novel therapeutic targets for the treatment of muscular dystrophies.</p>
</abstract>
<kwd-group>
<kwd>muscular dystrophy</kwd>
<kwd>genetic modifier</kwd>
<kwd>variant</kwd>
<kwd>muscle disease</kwd>
<kwd>DMD</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>